Articles found by an AI-assisted PubMed search that may be missing from CancerImmunoDB, shared so that curators and users can see what is being considered.
Why this exists: the database holds only about 10 articles a year for 2021–2024, and a plain PubMed search cannot judge whether a paper fits the scope.
| Year | Screened | Likely relevant |
|---|---|---|
| 2026 | 99 | 61 |
| 2025 | 100 | 81 |
| 2024 | 98 | 72 |
| 2023 | 92 | 45 |
| 2022 | 100 | 52 |
| 2021 | 85 | 49 |
360 articles shown. “In the database” counts the entries the database already has for each drug the AI named (cell line / animal / patient).
| PMID | Year | Article | Drugs | Study type | Cancer type | In the database | Curator status |
|---|---|---|---|---|---|---|---|
| 40513067 | 2026 | Anti-angiogenic therapy combined with immune checkpoint blockade mediates CCR7 + CD8 + T-cell entry into HCC through high endothelial venules. Hepatology (Baltimore, Md.) Likely relevant The study evaluates anti-angiogenic therapy combined with immune checkpoint blockade in patients and orthotopic mouse liver tumor models, measuring HEV formation and T-cell infiltration. | anti-angiogenic drugs; immune checkpoint blockade | Mixed | hepatocellular carcinoma | anti-angiogenic drugs 0/0/0; immune checkpoint blockade 0/1/0 | Awaiting curator check |
| 40983502 | 2026 | Alleviated T cell exhaustion and SLC1A3-mediated stroma-remodelling dictate chemoimmunotherapy efficacy in oesophageal squamous cell carcinoma. Gut Likely relevant Examines the combination of chemotherapy and anti-PD-1 in patients and murine models, measuring effects on CD8+ T cells and immune checkpoints. | anti-programmed cell death protein-1 (PD-1) | Mixed | oesophageal squamous cell carcinoma | anti-programmed cell death protein-1 (PD-1) 0/0/0 | Awaiting curator check |
| 41092615 | 2026 | PD-L1 nanobody-engineered bacterial outer membrane vesicles delivering cuproptosis micelles for potentiated cancer immunotherapy. Biomaterials advances Likely relevant The study tests engineered nanoplatforms delivering elesclomol and immune checkpoint blockade in a mouse xenograft model and evaluates antitumor immune responses like CD8+ T cell infiltration. | elesclomol; PD-L1 nanobody-engineered bacterial outer membrane vesicles; immune checkpoint inhibitors | Animal | triple-negative breast cancer | elesclomol 0/0/0; PD-L1 nanobody-engineered bacterial outer membrane vesicles 0/0/0; immune checkpoint inhibitors 0/0/0 | Awaiting curator check |
| 41133967 | 2026 | Sequential Tumor Microenvironment Reprogramming by Nanoplatform Potentiates Sonodynamic-Chemodynamic Therapy and Immune Checkpoint Blockade in Breast Cancer. Advanced science (Weinheim, Baden-Wurttemberg, Germany) Likely relevant The study experimentally tests a nanoplatform combining sonodynamic-chemodynamic therapy agents and a PD-L1 antibody in murine breast cancer models, measuring effects on effector T cell infiltration and systemic immune responses. | manganese dioxide; calcium peroxide; chlorin e6; PD-L1 antibody | Animal | breast cancer | manganese dioxide 0/0/0; calcium peroxide 0/0/0; chlorin e6 0/0/0; PD-L1 antibody 0/1/0 | Awaiting curator check |
| 41255280 | 2026 | Combined Photothermal and mTOR-Targeted Therapy Overcomes Immune Evasion and Enhances Checkpoint Blockade Efficacy in Metastatic Triple-Negative Breast Cancer. Advanced science (Weinheim, Baden-Wurttemberg, Germany) Likely relevant The study tests a gold nanocomposite delivering photothermal and mTOR-targeted therapy (ASPPR∩A) combined with PD-1 blockade in cell lines and murine models, measuring immunogenic cell death, MHC-I presentation, and T-cell infiltration. | ASPPR∩A; PD-1 blockade | Mixed | triple-negative breast cancer | ASPPR∩A 0/0/0; PD-1 blockade 0/0/0 | Awaiting curator check |
| 41372408 | 2026 | Agonists for cytosolic bacterial receptor ALPK1 induce antitumour immunity. Nature Likely relevant Experimentally tests ALPK1 agonists (ADP-Hep and UDSP-Hep) alone and with checkpoint inhibitors in mice, measuring various immune readouts including CD8+ T cell and dendritic cell activation. | UDSP-Hep; ADP-Hep; checkpoint inhibitors | Animal | unspecified tumour | UDSP-Hep 0/0/0; ADP-Hep 0/0/0; checkpoint inhibitors 0/0/0 | Awaiting curator check |
| 41469103 | 2026 | P53-Armed Oncolytic Virotherapy Promotes the Efficacy of PD1 Blockade in Murine Osteosarcoma Tumors. Anticancer research Likely relevant The study tests oncolytic adenoviruses (OBP-301, OBP-702) and anti-PD1 in human and murine osteosarcoma cell lines and orthotopic mouse models, measuring immunogenic cell death markers and PD-L1/PD-L2 expression. | anti-PD1; OBP-301; OBP-702 | Mixed | osteosarcoma | anti-PD1 1/1/0; OBP-301 0/0/0; OBP-702 0/0/0 | Awaiting curator check |
| 41484455 | 2026 | Pseudomonas aeruginosa induces tumor pyroptosis and immune activation to enhance checkpoint blockade in colorectal cancer. Cancer immunology, immunotherapy : CII Likely relevant The study tests P. aeruginosa and anti-PD-L1 antibody in vitro and in vivo, and measures immunogenic cell death, cytokine secretion, dendritic cell maturation, and CD8+ T cell infiltration. | anti-PD-L1 antibody; Pseudomonas aeruginosa | Mixed | colorectal cancer | anti-PD-L1 antibody 0/1/0; Pseudomonas aeruginosa 0/0/0 | Awaiting curator check |
| 41485690 | 2026 | Gu-Jin-Xiao-Ji Decoction potentiates anti-PD-1 immunotherapy in lung cancer by inhibiting the PI3K/AKT/NF-κB/PD-L1 axis. Fitoterapia Likely relevant The study experimentally tests Gu-Jin-Xiao-Ji Decoction and a PD-1 inhibitor in mice and measures immune cell infiltration and cytokine levels. | Gu-Jin-Xiao-Ji Decoction; PD-1 inhibitor | Animal | lung cancer | Gu-Jin-Xiao-Ji Decoction 0/0/0; PD-1 inhibitor 0/0/0 | Awaiting curator check |
| 41491256 | 2026 | Engineering bispecific exosome activators of T cells to target immune checkpoint inhibitor-resistant metastatic melanoma. Nature biotechnology Likely relevant The study tests bispecific exosome activators (BEAT) targeting PD-L1 and Wnt7b in melanoma mouse models and measures CD8+ T cell recruitment and activation. | PD-1 inhibitor; anti-PD-L1; anti-Wnt7b | Animal | Melanoma | PD-1 inhibitor 0/0/0; anti-PD-L1 0/15/0; anti-Wnt7b 0/0/0 | Awaiting curator check |
| 41501177 | 2026 | SLC2A1+ tumour-associated macrophages spatially control CD8+ T cell function and drive resistance to immunotherapy in non-small-cell lung cancer. Nature cell biology Likely relevant Tests SLC2A1 genetic deletion/inhibition and alpha-PD-L1 in murine tumor models, measuring CD8+ T cell distribution and effector function. | alpha-PD-L1; SLC2A1 inhibitor | Animal | non-small-cell lung cancer | alpha-PD-L1 0/0/0; SLC2A1 inhibitor 0/0/0 | Awaiting curator check |
| 41528176 | 2026 | 131I-Labeled Dual Immune Checkpoint Inhibitors for Tumor Microenvironment Improvement To Enhance Antitumor Efficacy. Molecular pharmaceutics Likely relevant Experimentally tests a radiolabeled bispecific antibody in tumor-bearing mice and reports effects on CD8+ T cell infiltration, immunogenic cell death, and neutrophil activity. | 131I-labeled cadonilimab; AK104 | Animal | non-small-cell lung cancer | 131I-labeled cadonilimab 0/0/0; AK104 0/0/0 | Awaiting curator check |
| 41538362 | 2026 | EGFR activation disrupts immunotherapy response via SHP2-mediated suppression of tumor-intrinsic response to IFN-γ. The Journal of clinical investigation Likely relevant The study experimentally tests SHP2 inhibition and immune checkpoint blockade in cancer models and investigates their effects on IFN-g responsiveness and T cell infiltration. | immune checkpoint blockade; SHP2 inhibitor | Mixed | lung cancer | immune checkpoint blockade 0/1/0; SHP2 inhibitor 0/0/0 | Awaiting curator check |
| 41580015 | 2026 | Copper ionophores drive divergent responses to immune checkpoint inhibition across colorectal tumor models. Cancer letters Likely relevant Evaluates copper ionophores and PD-1 blockade in syngeneic colorectal cancer models and measures immune cell infiltration and calreticulin exposure. | diethyldithiocarbamate; clioquinol; programmed cell death protein 1 (PD-1) blockade | Animal | colorectal cancer | diethyldithiocarbamate 0/0/0; clioquinol 0/0/0; programmed cell death protein 1 (PD-1) blockade 0/0/0 | Awaiting curator check |
| 41591489 | 2026 | Decorin facilitates T cell-mediated antitumor immunity and augments the efficacy of anti-PD1 immunotherapy. Cancer immunology, immunotherapy : CII Likely relevant The study experimentally tests Decorin overexpression in combination with an anti-PD1 antibody in mouse tumor models and measures CD8+ T cell infiltration and cytokine production. | anti-PD1 antibody | Animal | cancer | anti-PD1 antibody 0/0/0 | Awaiting curator check |
| 41612693 | 2026 | Tumor cell AMPK activation enhances NK cell anti-tumor immunity and synergizes with PD-L1 blockade therapy. Molecular therapy : the journal of the American Society of Gene Therapy Likely relevant The study tests pharmacological/genetic modulators and PD-L1 checkpoint blockade in mice, assessing NK cell-mediated killing and immune-related gene signatures. | PD-1 / PD-L1 pathway inhibitors; AMPK activators/inhibitors | Animal | cancer (general / unspecified in title) | PD-1 / PD-L1 pathway inhibitors 0/0/0; AMPK activators/inhibitors 0/0/0 | Awaiting curator check |
| 41622807 | 2026 | Potentiating Chemo-Immunotherapy via a Programmable Nanocapsule-Hydrogel Platform for Sequential Tumor Microenvironment Remodeling. Advanced materials (Deerfield Beach, Fla.) Likely relevant The study evaluates a delivery platform combining oxaliplatin and anti-PD-L1 in a murine breast tumor model, assessing immunogenic stress and T cell persistence. | oxaliplatin; anti-PD-L1 | Animal | breast cancer | oxaliplatin 12/5/2; anti-PD-L1 0/15/0 | Awaiting curator check |
| 41653296 | 2026 | Digital spatial profiling reveals additive effects of triple therapy on tumor microenvironment: anti-PD-L1, anti-VEGF, and PARP inhibition in mouse models. Cancer immunology, immunotherapy : CII Likely relevant The study tests anti-PD-L1, anti-VEGF, and PARP inhibitors in mouse models and measures immune readouts including CD8+ Granzyme B+ cell infiltration and HEV formation. | anti-PD-L1; anti-VEGF; PARP inhibitor; PARPi | Animal | ovarian cancer | anti-PD-L1 0/15/0; anti-VEGF 0/0/0; PARP inhibitor 0/0/0; PARPi 0/0/0 | Awaiting curator check |
| 41663641 | 2026 | Immune checkpoint inhibition increases antigen-specific T cell response in head and neck cancer. Scientific reports Likely relevant The study tests immune checkpoint inhibitors such as anti-PD-1 in mixed lymphocyte-peptide cultures with head and neck cancer cell lines and measures antigen-specific T cell responses. | anti-PD-1; LAG-3; TIM-3 | Cell line | Head and neck cancer | anti-PD-1 14/36/0; LAG-3 0/0/0; TIM-3 0/0/0 | Awaiting curator check |
| 41666678 | 2026 | PD-L1-targeted photodynamic therapy orchestrates checkpoint blockade and immunogenic cell death for synergistic cancer immunotherapy. Redox biology Likely relevant The study tests a Photodegradation-Targeting Chimera combining verteporfin in mouse models and measures adaptive antitumor immunity and immunogenic cell death. | verteporfin; PPA-VPF | Animal | unspecified tumor models | verteporfin 0/0/0; PPA-VPF 0/0/0 | Awaiting curator check |
| 41667239 | 2026 | KRAS-driven protein disulfide isomerase family A member 6 expression suppresses PRKR-like endoplasmic reticulum kinase-mediated immunogenic cell death to desensitise pancreatic ductal adenocarcinoma to immune checkpoint blockers. Gut Likely relevant The study tests the PDIA6 inhibitor PACMA31 in mouse models and measures CD8+ T cells and immunogenic cell death. | PACMA31; immune checkpoint blockers (ICBs) | Animal | pancreatic ductal adenocarcinoma | PACMA31 0/0/0; immune checkpoint blockers (ICBs) 0/0/0 | Awaiting curator check |
| 41671386 | 2026 | SAICAR Drives T Regulatory Cell Differentiation and FOXP3 Maintenance to Promote Immunotherapy Resistance. Cancer research Likely relevant The study experimentally tests anti-PD-1 and 6-mercaptopurine in human tumors and mouse models and measures effects on Treg differentiation, FOXP3, and effector T-cell function. | anti-PD-1; 6-mercaptopurine | Mixed | cancer | anti-PD-1 14/36/0; 6-mercaptopurine 0/0/0 | Awaiting curator check |
| 41677856 | 2026 | Stoking an anti-liver cancer immune response with cryoablation plus an intratumoral TLR9 agonist and dual checkpoint inhibitors. Cancer immunology, immunotherapy : CII Likely relevant The study tests cryoablation combined with CpG and dual checkpoint inhibitors in mice and measures immune cell profiles and cytokine levels. | anti-PD-1; anti-CTLA-4; CpG | Animal | hepatocellular carcinoma | anti-PD-1 14/36/0; anti-CTLA-4 1/10/7; CpG 0/1/0 | Awaiting curator check |
| 41723880 | 2026 | Reprogramming tumour-associated macrophages in breast cancer via si-FOXM1-loaded lipid nanoparticles enhances immune checkpoint inhibitor efficacy. British journal of pharmacology Likely relevant The study tests lipid nanoparticles loaded with si-FOXM1 in vitro and in vivo xenograft models and measures their effect on reprogramming tumor-associated macrophages to the M1 phenotype. | si-FOXM1-loaded lipid nanoparticles | Mixed | breast cancer | si-FOXM1-loaded lipid nanoparticles 0/0/0 | Awaiting curator check |
| 41734997 | 2026 | Serotonin transporter SERT: a novel immune checkpoint for CD8+ T cell antitumor therapy. Journal for immunotherapy of cancer Likely relevant Tests selective serotonin reuptake inhibitors (SSRIs) and anti-PD-1 therapy in mouse models and human xenografts and measures their effects on CD8+ T cell antitumor responses. | selective serotonin reuptake inhibitors; SSRIs; anti-PD-1 therapy | Mixed | unspecified cancer | selective serotonin reuptake inhibitors 0/0/0; SSRIs 0/0/0; anti-PD-1 therapy 0/0/0 | Awaiting curator check |